Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Are we expecting too much from the EMA’s MLM service?

Posted on December 16th, 2015 by in Pharmacovigilance

ema logo
At the beginning of September 2015, the EMA launched the Medical Literature Monitoring (MLM) service. I¬†recently read¬†the EMA’s MLM launch phase closure report in addition to¬†information from a recent EMA information day and have highlighted some key points below. (more…)

Screening Scientific Literature for Adverse Drug Reactions: Relevant for Patient Safety or Just a Time-Consuming Regulatory Obligation?

Posted on November 16th, 2015 by in Pharmacovigilance

An adverse drug reaction (ADR) is defined as any response to a medicinal product which is noxious and unintended. ADRs are a major public health problem, accounting¬†for up to 5% of all hospital admissions and 28% of the emergency visits. Of all hospitalized patients, 5% experience an ADR during the hospitalization (more…)

Ensuring the Safety of New Antipsychotics

Posted on October 30th, 2015 by in Chemistry

Antipsychotics have complex pharmacological profiles and adverse events are common with long-term use. New or optimized drugs with better safety profiles are desirable. The best way to get information on a new compound that has potential as an antipsychotic is to use in silico profiling to compare it to existing drugs, as described in this new paper.

Read all about drug safety of new antipsychotics.

  1. 1
  2. …
  3. 3
  4. 4
  5. 5